# ScoreItem: Lipoprote√≠na A

**ID:** `019bf31d-2ef0-7401-8c83-7a09665eb36a`
**FullName:** Lipoprote√≠na A (Exames - Laboratoriais)
**Unit:** nmol/L

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 10 artigos
- Avg Similarity: 0.668

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7401-8c83-7a09665eb36a`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7401-8c83-7a09665eb36a",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Lipoprote√≠na A (Exames - Laboratoriais)
**Unidade:** nmol/L

**30 chunks de 10 artigos (avg similarity: 0.668)**

### Chunk 1/30
**Article:** 2024: The year in cardiovascular disease ‚Äì the year of lipoprotein(a). Research advances and new findings (2024)
**Journal:** Archives of Medical Science
**Section:** abstract | **Similarity:** 0.743

Comprehensive review of research advances in lipoprotein(a) during 2024, including epidemiology, pathophysiology, genetic determinants, cardiovascular risk assessment, and emerging therapeutic strategies. The review highlights Lp(a) as an independent causal risk factor for atherosclerotic cardiovascular disease affecting 1.5 billion people worldwide, with levels 70-90% genetically determined.

---

### Chunk 2/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.740

ted jointly with the Lp(a) cholesterol. Lp(a), es-
pecially at high concentrations, may result in over-estimation of the calculated/determined LDL-C 
level. The LDL-C level can be adjusted to the Lp(a) 
level calculated using the Dahlen modiÔ¨Åcation of Table VIII. ClassiÔ¨Åcation of Lp(a) levels according to cardiovascular risk category. Based on PCS/PoLA 2024 recom-mendations [81]
Target valueElevated valuesLipoprotein(a)< 30 mg/dl  (< 75 nmol/l)30¬ñ50 mg/dl (75¬ñ125 nmol/l) Moderate cardiovascular risk> 50¬ñ180 mg/dl (> 125¬ñ450 nmol/l) High cardiovascular risk> 180 mg/dl (> 450 nmol/l) Very high cardiovascular risk

Arch Med Sci 2, March / 2024 371the Friedewald formula, based on the assumption that cholesterol accounts for 30% of the Lp(a) par-ticle mass [10, 79]: LDL-Ccor = LDL-Ccal/means ¬ñ [Lp(a) √ó 0.3] (all concen-trations in mg/dl).
RecommendationsIt is recommended that Lp(a) level should be measured at least once in every adult¬ís lifetime.

---

### Chunk 3/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** methods | **Similarity:** 0.714

quation 
based on the standard lipid panel for calculating small 
dense low-density lipoprotein-cholesterol and its use as 
a¬†risk-enhancer test. Clin Chem 2021; 67: 987-97.72. Marcovina SM, Albers JJ. Lipoprotein (a) measurements 
for clinical application. J Lipid Res 2016; 57: 526-37.73. Banach M, Penson PE. Statins and Lp(a): do not make 
perfect the enemy of excellent. Eur Heart J 2020; 41: 
190-1.74. Ferretti G, Bacchetti T, Johnston TP, et al. Lipoprotein(a): 
a¬†missing culprit in the management of athero-throm-
bosis? J Cell Physiol 2018; 233: 2966-81.75. Banach M. Lipoprotein (a) ¬ñ we know so much yet 
still have much to learn¬Ö J Am Heart Assoc 2016; 5: 
e003597.76. Cao J, SteÔ¨Äen BT, Guan W, et al. Evaluation of lipopro-
tein(a) electrophoretic and immunoassay methods in 
discriminating risk of calciÔ¨Åc aortic valve disease and 
incident coronary heart disease: the multi-ethnic study 
of atherosclerosis. Clin Chem 2017; 63: 1705-13.77.

---

### Chunk 4/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.713

means ¬ñ [Lp(a) √ó 0.3] (all concen-trations in mg/dl).
RecommendationsIt is recommended that Lp(a) level should be measured at least once in every adult¬ís lifetime. Measurement of 
Lp(a) should be considered in all patients with prema-
ture cardiovascular disease, non-responders to statin 
therapy, and individuals with a¬†border intermediate/
high risk, to ensure better risk stratiÔ¨Åcation1.It is recommended that re-measurement of Lp(a) be 
performed using a¬†test that gives the result in nmol/l 
(reÔ¨Çecting the number of Lp(a) molecules) for better 
risk stratiÔ¨Åcation. Screening of relatives of people with 
high Lp(a) levels should be considered1.In the case of patients with an Lp(a) level determined 
as part of an extended lipid proÔ¨Åle, the LDL-C should be 
adjusted using Dahlen¬ís modiÔ¨Åcation.

---

### Chunk 5/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.711

 s modiÔ¨Åcation. 1Based on the PSC/PoLA 2024 Guidelines [81].Lipid proÔ¨Åle ¬ñ laboratory reportLipid proÔ¨Åle includes a¬†battery of blood serum or plasma tests and calculations aimed at identiÔ¨Å-cation of dyslipidemia as a¬†cardiovascular risk fac-tor, deÔ¨Åning the recommendations and  treatment  
monitoring, including:¬ñ total cholesterol (TC) level,¬ñ HDL cholesterol level (HDL-C),¬ñ LDL cholesterol level (LDL-C),¬ñ non-HDL cholesterol level (non-HDL-C),
¬ñ triglyceride (TG) level,¬ñ  lipoprotein (a) level [Lp(a)] (determined at least once in life ¬ñ see PCS/PoLA 2024 recommenda-
tions [81]),¬ñ apolipoprotein B (apoB) level ¬ñ as indicated.In addition  to the results of measurements and calculations, a¬†lipid proÔ¨Åle laboratory report  (Table IX), should include information on how the LDL-C level was determined (calculated/deter-mined), as well as the target (desirable) and alarm-Table IX.

---

### Chunk 6/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.706

, apoiando a personaliza√ß√£o baseada em perfis de risco cumulativos, n√£o em um √∫nico marcador.
**Achados Adicionais**
- O cardi√¥metro de mortalidade cardiovascular iniciou monitoramento em 11/6/2024, contextualizando a urg√™ncia de interven√ß√µes cont√≠nuas.
- Diretrizes de tratamento costumam usar um limiar de 7,5% de risco para estatinas, mas exemplos pr√°ticos ilustram faixas de 2‚Äì4% em que a decis√£o deve considerar CAC e ApoB.
- Quase 40% dos indiv√≠duos com LDL muito elevado podem n√£o apresentar aterosclerose, refor√ßando heterogeneidade do risco.
- Colesterol total de 300 frequentemente acompanha LDL >190, mas a decis√£o terap√™utica deve ser guiada por risco global.
- Revis√µes de 2019 na Annals of Internal Medicine sobre carne vermelha/processada fornecem contexto adicional para dietas cardiometab√≥licas.
- Editorial de 2020 sobre hipercolesterolemia familiar difundiu o conceito ‚ÄúPower of Zero‚Äù, ampliando o uso do CAC na estratifica√ß√£o.

---

### Chunk 7/30
**Article:** Lipoprotein (a) in primary cardiovascular disease prevention is actionable today (2025)
**Journal:** JACC: Advances
**Section:** abstract | **Similarity:** 0.704

This review highlights the contemporary scientific foundation supporting early Lp(a) measurement, elucidates its pathogenic mechanisms (pro-atherogenic, pro-thrombotic, and pro-inflammatory), evaluates the evolving therapeutic landscape, and proposes a pragmatic clinical framework for integrating Lp(a) into preventive cardiology practice today.

---

### Chunk 8/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.700

il√¢ncia aumentada nas mulheres.**
- Pr√©-menopausa: incid√™ncia de eventos cardiovasculares em mulheres √© muito menor (raz√µes 1:20 a 1:30 versus homens).
- P√≥s-menopausa: aproxima√ß√£o para quase 1:1, refletindo a perda do efeito protetor do estrog√™nio e a mudan√ßa no perfil de risco.
**Additional Key Findings**
- Limiares de exposi√ß√£o/oxida√ß√£o do LDL: acima de 0,8 h√° maior exposi√ß√£o do LDL √† oxida√ß√£o; alvo desej√°vel ‚â§0,7‚Äì0,8.
- Evid√™ncia hist√≥rica (Interarte, 2004) e revis√µes recentes (2023) sustentam a evolu√ß√£o do conhecimento sobre D, resist√™ncia √† insulina e risco cardiovascular.
- Lp(a) tem ~90% de variabilidade gen√©tica, indicando forte determina√ß√£o heredit√°ria e necessidade de estrat√©gias espec√≠ficas.
- Semaglutida em IC diast√≥lica e obesidade: estudo com n=529 mostrou redu√ß√£o de peso de 10% e apenas 1 evento de morte por IC no grupo tratado, sugerindo benef√≠cio cl√≠nico.

---

### Chunk 9/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.693

criminating risk of calciÔ¨Åc aortic valve disease and 
incident coronary heart disease: the multi-ethnic study 
of atherosclerosis. Clin Chem 2017; 63: 1705-13.77. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipopro-
tein(a) as a¬†cardiovascular risk factor: current status. 
Eur Heart J 2010; 31: 2844-53.78. Tsimikas S. A¬†test in context: lipoprotein(a) diagnosis, 
prognosis, controversies, and emerging therapies. JACC 
2017; 69: 692-711.79. Li KM, Wilcken DE, Dudman NP. EÔ¨Äect of serum lipopro-
tein(a) on estimation of low-density lipoprotein choles-
terol by the Friedewald formula. Clin Chem 1994; 40: 
571-3.80. Kronenberg F. Lipoprotein(a) measurement issues: are 
we making a¬†mountain out of a¬†molehill? Atherosclero-
sis 2022; 349: 123-35.81. Sosnowska B, Stepinska J, Mitkowski P, et al. Recom-
mendations of the Experts of the Polish Cardiac Soci-
ety (PCS) and the Polish Lipid Association (PoLA) on the 
diagnosis and management of elevated lipoprotein(a) 
levels.

---

### Chunk 10/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.681

co da dislipidemia.
- [ ] 2. Analisar criticamente os estudos sobre o Inclisiran (Cibrava), focando na diferen√ßa entre desfechos substitutos (redu√ß√£o de LDL) e desfechos cl√≠nicos duros (mortalidade, infarto, AVC).
- [ ] 3. Utilizar o site `the-nnt.com` para pesquisar o NNT e NNH de outros medicamentos prescritos na pr√°tica cl√≠nica.
- [ ] 4. Refletir sobre a influ√™ncia da ind√∫stria farmac√™utica e dos interesses financeiros na prescri√ß√£o de novos medicamentos.
- [ ] 5. Estudar a diferen√ßa entre risco relativo e risco absoluto para interpretar criticamente os achados de estudos cient√≠ficos.
- [ ] 6. Pesquisar sobre os diferentes tipos de √¥mega-3 (EPA, DHA, ALA) e suas formula√ß√µes para entender como a qualidade do suplemento afeta os resultados.
- [ ] 7. Investigar os exames de subfracionamento de LDL e a rela√ß√£o ApoA/ApoB como ferramentas de avalia√ß√£o de risco cardiovascular mais precisas que o LDL total.
- [ ] 8.

---

### Chunk 11/30
**Article:** A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice (2024)
**Journal:** Journal of Clinical Lipidology
**Section:** abstract | **Similarity:** 0.679

Updated National Lipid Association (NLA) guidelines recommending universal one-time screening of Lp(a) in all adults. The document provides risk stratification criteria, clinical decision-making algorithms, and recommendations for intensified cardiovascular risk reduction in individuals with elevated Lp(a) levels (>50 mg/dL or >125 nmol/L).

---

### Chunk 12/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.671

vida e identificar fatores de risco para inflama√ß√£o e disfun√ß√£o endotelial (dieta, estresse, sedentarismo).
- [ ] 2. Utilizar a calculadora MESA Risk para determinar o risco cardiovascular dos pacientes e considerar a solicita√ß√£o do Escore de C√°lcio Coronariano antes de prescrever estatinas em preven√ß√£o prim√°ria.
- [ ] 3. Ao avaliar o risco cardiovascular, solicitar exames avan√ßados como a rela√ß√£o ApoB/ApoA, subpart√≠culas de lipoprote√≠nas e anti-LDL oxidado para uma an√°lise mais aprofundada.
- [ ] 4. Em pacientes de preven√ß√£o prim√°ria, mesmo com colesterol alto, priorizar mudan√ßas no estilo de vida antes de considerar o uso de estatinas.
- [ ] 5. Reservar o uso de estatinas principalmente para pacientes em preven√ß√£o secund√°ria ou de alt√≠ssimo risco, focando nos seus efeitos pleotr√≥picos.
- [ ] 6.

---

### Chunk 13/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.664

enos de um caso adicional por mil pessoas em 10 anos, sobre um risco basal de 1,5%).
**Novas terapias como o Inclisiran prometem uma redu√ß√£o dr√°stica de 50% no colesterol LDL, mas a um custo elevado de 6 a 8 mil reais por inje√ß√£o.**
- A inje√ß√£o, conhecida como "vacina do colesterol", demonstrou uma redu√ß√£o de 50% nos n√≠veis de LDL e colesterol.
- O custo de cada aplica√ß√£o varia entre 6 e 8 mil reais.
### Achados Adicionais Relevantes
- N√≠veis mais altos de HDL, tradicionalmente visto como "colesterol bom", foram associados a um risco aumentado de doen√ßa cardiovascular (Hazard Ratio de 1.15) e doen√ßa coronariana (Hazard Ratio de 1.26-1.27).
- Uma redu√ß√£o de risco absoluto de 3% para infarto em pacientes de alto risco √© considerada muito significativa, equivalendo a 30 vidas salvas a cada mil pacientes.
- Um estudo sobre part√≠culas de LDL administrou uma dose de 2 gramas de √¥mega-3 duas vezes ao dia.

---

### Chunk 14/30
**Article:** Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association (2024)
**Journal:** Journal of Clinical Lipidology
**Section:** abstract | **Similarity:** 0.658

Consenso da National Lipid Association estabelecendo que apolipoprote√≠na B (apoB) √© medida cl√≠nica validada que complementa painel lip√≠dico padr√£o. ApoB quantifica diretamente n√∫mero de part√≠culas aterog√™nicas (cada part√≠cula LDL, VLDL, IDL cont√©m uma mol√©cula apoB), sendo preditor superior ao LDL-C isolado especialmente em pacientes com diabetes, s√≠ndrome metab√≥lica, triglicer√≠deos elevados ou em uso de estatinas. Recomenda dosagem de apoB para estratifica√ß√£o de risco mais precisa e ajuste terap√™utico em pacientes de risco intermedi√°rio a alto. Metas sugeridas: <80 mg/dL (risco moderado), <70 mg/dL (alto risco), <55 mg/dL (muito alto risco). Estudos de discord√¢ncia demonstram que quando LDL-C, colesterol n√£o-HDL e apoB n√£o est√£o alinhados, risco cardiovascular segue mais proximamente apoB e n√£o-HDL, refletindo melhor potencial aterog√™nico real.

---

### Chunk 15/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.653

e altera√ß√µes renais; interven√ß√£o com complexos de vitaminas B.
### 7. Lipoprote√≠na(a) [Lp(a)]
- Gen√©tica e risco:
  - Forte heran√ßa (~90%); pr√≥-tromb√≥tica e pr√≥-inflamat√≥ria; carrega lip√≠dios oxidados e interfere na fibrin√≥lise.
- Mecanismos e terapias:
  - LDL oxidado ativa NLRP3 e NF-Œ∫B; terapias: vitamina C, niacina (efeito modesto), estatinas (baixa resposta), PCSK9i (reduz substrato LDL), plasmaf√©rese; TRH em casos indicados pode reduzir Lp(a).
- Glicoc√°lix:
  - Estrutura acima do endot√©lio em investiga√ß√£o como alvo terap√™utico.
### 8. Rela√ß√£o APO-A/APO-B
- Import√¢ncia da raz√£o:
  - Raz√£o APO-B/APO-A ideal ‚â§0,7‚Äì0,8; acima de 0,8 aumenta exposi√ß√£o do LDL √† oxida√ß√£o e risco ateroscler√≥tico (INTERHEART).
### 9. Altera√ß√µes hormonais: testosterona e estrog√™nio
- Defici√™ncias e risco:
  - Baixa testosterona/estradiol/DHEA-S associam-se a hipertens√£o, dislipidemia, resist√™ncia √† insulina, aumento de IMC e maior mortalidade cardiovascular.

---

### Chunk 16/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.650

re present in higher concentrations, while 
particles of a¬†higher mass (high number of KIV-2 re-peats) are present in lower concentrations [10, 72].Lp(a) level is a¬†risk factor independent of LDL-C for ASCVD, calciÔ¨Åed aortic stenosis, peripher-al artery disease or ischaemic stroke. In Poland, 
Lp(a) levels are measured too infrequently and knowledge of them is inadequate. Therefore, ev-ery eÔ¨Äort should be made to change this as soon as possible, as increased Lp(a) levels occur quite frequently. According to available data, up to 30% of patients with familial hypercholesterolaemia 
and/or acute coronary syndrome may have Lp(a) 
concentrations above 125 nmol/l (50 mg/dl), with often desirable LDL-C levels.

---

### Chunk 17/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** introduction | **Similarity:** 0.649

ffective monitoring (after therapy 
initiation), and in the consequence to avoid the first and recurrent cardio-
vascular events.Key words: lipid disorders, low-density lipoprotein cholesterol,  high-density lipoprotein cholesterol (HDL-C), triglicerides, non-HDL-C, guidelines, laboratory diagnostics.
Editor¬ís choice 

358 Arch Med Sci 2, March / 2024IntroductionThe lipid proÔ¨Åle routinely performed to assess cardiovascular risk involves the measurement/calculation of serum/plasma levels of total cho-
lesterol (TC), high-density lipoprotein cholester-ol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and non-HDL choles-terol (non-HDL-C), although LDL-C level is still the most important factor in both the diagnosis and 
monitoring of the course and treatment of lipid 
disorders and the prediction of cardiovascular in-
cidents [1¬ñ4].

---

### Chunk 18/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.647

ipoprote√≠na(a), raz√£o APO-A/APO-B, al√©m de avaliar altera√ß√µes hormonais (testosterona, estrog√™nio, DHEA-S), obesidade e sono. S√£o discutidas evid√™ncias (Framingham; revis√µes 2023‚Äì2024; ensaios com semaglutida; alvos para Lp(a) como lepodisir√£) e mecanismos fisiopatol√≥gicos (NF-Œ∫B, NLRP3, PI3K/AKT vs MAPK, GLUT4, estresse oxidativo, mitoc√¥ndria, lipotoxicidade, exossomas, ferroptose), culminando em estrat√©gias terap√™uticas pr√°ticas (suplementa√ß√£o de √¥mega 3, ajuste da vitamina D com PTH, metformina, inibidores de PCSK9, niacina, terapia de reposi√ß√£o hormonal, agonistas GLP-1). O instrutor evidencia lacunas nos guidelines quanto aos pilares de estilo de vida e defende abordagem integrada com nutrigen√©tica/nutrigen√¥mica. Data de cria√ß√£o: 2025-11-20.
## üîñ Conhecimento
### 1.

---

### Chunk 19/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.646

t al. Recom-
mendations of the Experts of the Polish Cardiac Soci-
ety (PCS) and the Polish Lipid Association (PoLA) on the 
diagnosis and management of elevated lipoprotein(a) 
levels. Arch Med Sci 2024; 20: 8-27.

---

### Chunk 20/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.646

pid 
disorders and the prediction of cardiovascular in-
cidents [1¬ñ4]. It is worth emphasising, however, 
that since 2021 non-HDL-C has been treated as equivalent to LDL-C in the assessment of the lipid proÔ¨Åle [5]. Similarly, there is no longer any doubt 
that it would be optimal to assess the number of 
atherogenic lipoprotein particles (rather than the 
mass of their components). Determination of apo-
lipoprotein B (apoB) is still not a¬†regular part of the 
lipid proÔ¨Åle.  The results of lipid proÔ¨Åle determinations indi-rectly, and approximately, reÔ¨Çect the content of the 
individual lipoproteins in the blood. Of particular 
importance in the laboratory assessment of lipid 
metabolism and the risk of progression of athero-
sclerosis is the quantitative measurement of ath-erogenic lipoproteins, i.e. LDL, lipoprotein(a) [Lp(a)], chylomicron (CM) remnants and very low-density 
lipoprotein (VLDL) remnants [2, 3].

---

### Chunk 21/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** methods | **Similarity:** 0.644

d include information on 

Arch Med Sci 2, March / 2024 369the desirable (target) values with regard to cardio-vascular risk (Table VI).
RecommendationsNon-HDL-C is an indicator of cardiovascular risk, partic-ularly recommended in individuals with TG levels > 200 
mg/dl (2.3 mmol/l), obesity, type 2 diabetes, metabolic 
syndrome and low TC and LDL-C levels. 
Based on the PoLA Guidelines (2021) it is equivalent to 
LDL-C cholesterol as a¬†predictor and should be assessed in 
every patient as a¬†permanent element of the lipid proÔ¨Åle. Apolipoprotein B Apolipoprotein B (apoB), which is a¬†structural component of all lipoproteins except for HDL, ex-ists in two isoforms: apoB100 (MM 550 kD), syn-
thesised in hepatocytes and present in VLDL, IDL and LDL, and its fragment, apoB48 (MM 265 kD), synthesised in enterocytes and present in CM and their remnants [10, 69].Methods of determinationSerum/plasma apoB is determined by immuno- turbidimetry and immunonephelometry.

---

### Chunk 22/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** methods | **Similarity:** 0.642

gically using PCSK9 inhibitors, inclisir-an, or ultimately medicines dedicated to lowering 
Lp(a) levels, such as pelacarsen or olpasiran, which will further increase the need for assays [73¬ñ75].Methods of determinationThe serum/plasma Lp(a) level is determined main-ly by immunoturbidimetry and immunonephelome-try. Determinations should preferably be performed 
using fresh material. Standardisation of these meth-
ods is based on the metrological consistency of the calibrators with the original IFCC/WHO reference ma-terial. The results obtained using diÔ¨Äerent methods 
are still insuÔ¨Éciently harmonised, which is thought to result from the eÔ¨Äect of the apo(a) molecule size variability on Lp(a) immunoassays.

---

### Chunk 23/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** methods | **Similarity:** 0.640

apo(a) molecule, resulting in possible underestimation of the assayed Lp(a) levels of lower 
molecular weight (lower number of KIV2 repeats in apo(a)) and overestimation of the assayed Lp(a) lev-
els of higher molecular weight (higher number of KIV2 repeats in apo(a)). Methods using antibodies against non-repeat epitopes, such as the KV domain, are free from such interferences [76¬ñ80]. Because of the 
variation in the molecular weight of Lp(a), the results should be expressed in nmol/l (Table VIII) [81], reÔ¨Çect-ing the number and not the mass of Lp(a) molecules.Reporting of resultsAlongside the Lp(a) level, a¬†laboratory report should include information on desirable (target) and alarm values indicating cardiovascular risk (Table VIII).The LDL cholesterol level is determined or cal-culated jointly with the Lp(a) cholesterol. Lp(a), es-
pecially at high concentrations, may result in over-estimation of the calculated/determined LDL-C 
level.

---

### Chunk 24/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.640

enta online que usa par√¢metros cl√≠nicos e o escore de c√°lcio para estimar o risco cardiovascular em 10 anos. Possui limita√ß√µes por n√£o incluir marcadores da medicina integrativa.
*   **Uso Criterioso de Estatinas:**
    - **Preven√ß√£o Prim√°ria (baixo risco):** O uso √© controverso e muitas vezes desnecess√°rio, pois o NNT √© muito alto e os riscos de efeitos adversos podem superar os benef√≠cios.
    - **Preven√ß√£o Secund√°ria (p√≥s-evento):** O uso √© justificado pelo baixo NNT e pelos **efeitos pleotr√≥picos** da estatina, que incluem:
        - Redu√ß√£o da inflama√ß√£o e melhora da fun√ß√£o endotelial.
        - Diminui√ß√£o da oxida√ß√£o dentro da placa.
        - Estabiliza√ß√£o da placa, tornando-a menos propensa √† ruptura.
*   **Exames Cl√≠nicos Avan√ßados:**
    - **Subfracionamento das part√≠culas de LDL e HDL:** Avalia o tamanho e a quantidade das part√≠culas.
    - **Anti-LDL Oxidado:** Mede a taxa de oxida√ß√£o do colesterol.

---

### Chunk 25/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.638

acientes com doen√ßa cardiovascular pr√©via, o √¥mega-3 mostrou uma redu√ß√£o absoluta de risco de infarto de 3% (30 vidas salvas a cada 1.000 pessoas).
    - **Vieses do Estudo:** O estudo n√£o controlou tipo, qualidade ou dose do √¥mega-3, baseou-se em autorrelato e usou uma popula√ß√£o (UK Biobank) mais saud√°vel que a m√©dia, o que limita a generaliza√ß√£o dos resultados.
*   **Complexidade do Colesterol e Perfil Lip√≠dico**
    - **Paradoxo do HDL Alto:** N√≠veis muito altos de HDL podem, paradoxalmente, aumentar o risco cardiovascular, mostrando que a rela√ß√£o n√£o √© linear.
    - **Qualidade vs. Quantidade do LDL:** A qualidade das part√≠culas de LDL (tamanho e densidade) √© um preditor de risco mais importante que a quantidade total. Part√≠culas pequenas e densas (small dense LDL) s√£o mais aterog√™nicas.

---

### Chunk 26/30
**Article:** Cardiologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.637

lip√≠dico e risco cardiovascular.
## Objetivo:
- Refer√™ncia a estudos indicando que cerca de 50% dos indiv√≠duos com LDL ‚Äúnormal‚Äù (‚â§100 mg/dL) apresentam aterosclerose aos 50 anos.
- Proposta de avalia√ß√£o laboratorial:
  - Colesterol total, HDL, triglicer√≠deos, LDL (com possibilidade de subfracionamento).
  - Insulina de jejum, glicemia de jejum, hemoglobina glicada.
  - LDL oxidada direta; considerar anticorpos anti-LDL oxidada quando a direta n√£o estiver dispon√≠vel (menos fidedigno, por√©m informativo sobre resposta imune).
  - Subfracionamento de LDL (tamanho/densidade das part√≠culas), reconhecendo limita√ß√µes.
  - Apolipoprote√≠nas: ApoA (predominante em HDL) e ApoB (predominante em LDL); maior raz√£o ApoA/ApoB sugere melhor perfil de risco.
- Considerar angiotomografia de coron√°rias com escore de c√°lcio para avaliar placas e calcifica√ß√µes quando exames laboratoriais sugerirem alto risco, reconhecendo poss√≠veis discord√¢ncias entre exames s√©ricos e imagem.

---

### Chunk 27/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.634

50%Moderate< 100< 2.6Low< 115< 3.0Alarming levels:Suspected homozygous familial hypercholesterolaemia:In untreated individuals> 500> 13.0In treated individuals> 300> 7.8Suspected heterozygous familial hypercholesterolaemia> 190> 4.9Unit conversion: [mg/dl] √ó 0.026 = [mmol/l].less, as with the use of other formulas, the accu-racy of non-HDL-C calculation depends on the bi-ological and analytical variability of TC and HDL-C concentrations. However, the biological variability 
of HDL-C levels is much lower than that of other lipid parameters, especially TG. In addition, HDL-C concentrations are much lower than the TC levels, which minimises their eÔ¨Äect on changes in calcu-lated non-HDL-C concentrations.Reporting of resultsAlongside the calculated non-HDL-C level, a¬†laboratory report should include information on 

Arch Med Sci 2, March / 2024 369the desirable (target) values with regard to cardio-vascular risk (Table VI).

---

### Chunk 28/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.634

a AVC em 10 anos. Em contraste, para pacientes de alto risco, a redu√ß√£o de risco de infarto foi de 3%.
### 5. Complexidade do HDL e LDL na Sa√∫de Cardiovascular
- **HDL Alto:** Um estudo de coorte mostrou que participantes com HDL j√° alto (‚â•60 mg/dL) que o aumentaram ainda mais tiveram um risco maior de doen√ßa cardiovascular (Hazard Ratio de 1.15), desmistificando a ideia de que "quanto mais HDL, melhor".
- **Inibidores de SGLT2:** Uma meta-an√°lise mostrou que esses medicamentos, apesar de reduzirem o risco cardiovascular, aumentam o colesterol total, LDL e HDL. Isso levanta um paradoxo em rela√ß√£o √†s dietas low-carb, que t√™m efeito similar no perfil lip√≠dico e s√£o frequentemente criticadas.
### 6. Subpart√≠culas de LDL e sua Relev√¢ncia Cl√≠nica
- O LDL n√£o √© uma mol√©cula √∫nica, mas um conjunto de subtipos. As part√≠culas de LDL pequenas e densas (small dense LDL) s√£o mais aterog√™nicas.

---

### Chunk 29/30
**Article:** Cardiologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.633

de coron√°rias com escore de c√°lcio para avaliar placas e calcifica√ß√µes quando exames laboratoriais sugerirem alto risco, reconhecendo poss√≠veis discord√¢ncias entre exames s√©ricos e imagem.
- Conte√∫do educacional adicional:
  - Polimorfismos gen√©ticos e seus impactos potenciais em perfis lip√≠dicos e risco cardiovascular: APOA1, APOA5, APOC3, APOB (Apo B-48 e Apo B-100), APOE, LDLR, CETP, ABCG5/ABCG8, HMGCR (HMG-CoA redutase), LIPC (lipase hep√°tica), FABP2, LPL, PCSK9, FADS1/FADS2, MIRF/elongases, TCF7L2.
  - Interpreta√ß√£o cr√≠tica de desfechos substitutos (valores isolados de LDL, colesterol total, HDL) e √™nfase em avalia√ß√£o cl√≠nica integral.
- Explica√ß√£o fisiopatol√≥gica: LDL sofre m√∫ltiplas modifica√ß√µes no fluxo e na parede vascular; oxida√ß√£o √© etapa final da cascata que leva √† forma√ß√£o de c√©lulas espumosas via ativa√ß√£o macrof√°gica, contribuindo para aterog√™nese.

---

### Chunk 30/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.633

he LDL-C is not calculated. The equivalent indicator of cardiovascular risk is then the non-HDL-C or apoB level. When alarming values are detected, urgent medical consultation is indicated.

372 Arch Med Sci 2, March / 2024
ing levels of the assayed analytes. When severe dyslipidaemia is suspected, it should also include 
information on the need to seek urgent medical attention if the LDL-C level indicates a¬†possible di-
agnosis of heterozygous (> 190 mg/dl; 4.9 mmol/l) 
or homozygous (> 500 mg/dl; 13.0 mmol/l) famil-
ial hypercholesterolaemia (FH), if the Lp(a) level  > 125 nmol/l (> 50 mg/dl) indicates a¬†high risk of 
cardiovascular incidents, or the TG level > 880 mg/
dl (10.0 mmol/l) indicates, in addition to increased 
cardiovascular risk, a¬†high risk of acute pancreati-
tis or, in the case of some typical symptoms, a¬†risk of familial chylomicronaemia syndrome (FCS).

---

